HBV Hepatitis and Related Renal Nephropathies: Pathogenesis and Treatment

Maurizio Salvadori¹ and Aris Tsalouchos²

¹Department of Transplantation Renal Unit, Careggi University Hospital, Florence, Italy; ²Division of Nephrology and Dialysis Unit, Saints Cosmas and Damian Hospital, Pescia, Italy

Abstract

The extrahepatic manifestations of hepatitis B virus (HBV) infection include reactive arthritis, vasculitis (panarteritis nodosa), and primary glomerulonephritis (membranous nephropathy, membranoproliferative glomerulonephritis, and, less frequently, IgA nephropathy, focal and segmental glomerulosclerosis, and minimal change disease). No specific histomorphological patterns have been reported in association with HBV infection. The treatment of HBV-related glomerulopathies is essentially antiviral. Peginterferon and nucleos(t)ide drugs are the treatment of choice. Corticosteroids have been proved to be ineffective (except in panarteritis nodosa), while immunosuppressants can lead to exacerbation of HBV infection.

Keywords: antiviral treatment; HBcAg; HBeAg; HBsAg; hepatitis B-associated glomerulonephritis

Introduction

Hepatitis B virus (HBV) is probably the most common virus found globally, affecting approximately 400 million subjects worldwide, although its incidence is decreasing due to the vaccination. The most severe complication is the hepatocellular carcinoma (HCC) that represents the ninth cause of death (1). In addition to the hepatic disease, the HBV is a frequent cause of extra hepatic disorders, among which the most common are glomerulonephritis (GN), vasculitis, and arthritis.

Genetic and Structure of HBV

HBV may be distinguished in 10 different genotypes; each of them is further divided in several subtypes. Genotypes are distinguished according to alphabetical letters. According to the genotype and subtype, HBV has a different geographical localization and causes different aggressive diseases (2).

Initially, genotype A seemed to be the most frequent cause of glomerular disease (3), but, subsequently, a more accurate study (4) has not confirmed a significant association between HBV genotype and renal disease.

HBV is a member of Hepadnaviridae. HBV genome is represented by a round DNA. There are four genes encoded by the genome: C, X, P, and S. The core protein is encoded by the C gene (HBcAg). The early antigen (HBeAg) is derived from a proteolytic action of gene P. Gene S encodes the surface antigen (HBsAg) (5, 6). The structure of HBV is
important to explain its effects and, in particular, different pathogenetic pathways of glomerular disease.

**Extra Hepatic Manifestations of HBV Infection**

The principal targets of HBV are hepatocytes. According to the status of viral replication, different conditions have been described ranging from an immune-tolerant phase to an immune-reactive phase with occurrence of hepatic necrosis and fibrosis. As this phase prolongs or repeats, fibrogenesis develops with subsequent cirrhosis. HCC is a major complication that can occur in the presence or absence of cirrhosis (7).

Extra hepatic manifestations of HBV infection may include dermatological manifestations, such as keratolysis, urticaria, purpura, and lichen planus, systemic diseases, such as serum sickness syndrome, polyarthralgia, polyarthritis, and, most importantly, renal diseases (7, 8). The latter include membranous nephropathy (MN), membranoproliferative glomerulonephritis (MPGN), immunoglobulin A (IgA) nephropathy, and focal segmental glomerulosclerosis (FSGS) (9). Less frequently, minimal change disease (MCD) and amyloidosis have been described in association with HBV, although this association is debated. Additionally, polyarteritis nodosa (PAN) is strongly associated with HBV. The disease is characterized by a necrotizing small and medium vessel vasculitis.

**Pathogenesis**

Three different factors may contribute to the development of HBV-associated renal diseases:

1. HBV antigens containing immune complexes
2. Direct viral effect
3. Host and viral genetic factors

**Immune complexes**

The role of immune complexes containing an HBV antigen is a certain factor, although it is still controversial whether the immune complexes are formed *in situ* or come from the blood and trapped into glomerular structures.

Several HBV antigens have been documented in the glomeruli, including the surface antigen (HBsAg), the early antigen (HBeAg), and the core antigen (HBcAg) (10). HBsAg and HBcAg are large and cationic. Owing to the dimension and charged immune complexes, these antigens could favor the mesangial or subendothelial deposition and facilitate the development of MPGN or IgA nephropathy. Indeed, immune complexes containing HBsAg have been eluted from a patient affected by HBV-MPGN (11). The low molecular weight of HBcAg (300 kilodalton) and its cationic charge could favor transmembrane migration and their deposition in the subepithelial space (12). The role of HBeAg in determining membranous nephropathy is further documented by the fact that circulating HBeAg containing immune complexes correlate with the severity of the disease (13, 14).

After glomerular deposition or formation of immune complexes, the complement activation could justify glomerular damage (15, 16). Figure 1 explains the relationship between the antigens and the type of glomerular disease.

**Direct viral effect**

The expression of HBV-DNA in the glomeruli in the absence of antibodies could justify the direct effect of HBV in glomerular damage (17).

Diao et al. (18), putting in culture together with mesangial cells and HBV, documented cell proliferation and formation of extracellular matrix proteins.

**Host and viral genetic factors**

HBV-associated glomerular disease may be linked to specific major histocompatibility complex class II alleles such as DQB1*0603 for membranous nephropathy and DRB1*1502 for MPGN (19, 20).

We have mentioned the possible relationship between different genotypes of HBV and associated nephropathy. Further studies have found that mutations in HBV genes (C1653T, A1726C, A1727T, C1730G, T1753C, A1762T, and G1764A) are present in 84% of patients with membranous nephropathy (21).

**Clinical Aspects**

**Membranous nephropathy**

The natural history of HBV-related membranous nephropathy seems to differ in children and adults.

---

**Figure 1:** Glomerular syndromes associated with an HBV carrier state. MN: membranous nephropathy; MPGN: membranoproliferative glomerulonephritis; PAN: polyarteritis nodosa; MC: mixed cryoglobulinemia; FSGS: focal segmental glomerulosclerosis.
Children often present with proteinuria in the nephrotic range with associated microematuria and hypertension. Kidney function as evaluated by estimated glomerular filtration rate (eGFR) is generally preserved. The natural history in children is often benign with a remission rate of 64% at 4 years (22). The disease prevails in males as idiopathic MN (23). HBV-MN in adults has a worse evolution in comparison to children. A declining eGFR has been observed in 29% of patients and one-third patients develop end-stage renal disease (ESRD) (24).

The deposition of immune complexes is typically in the subepithelial space because of their small size. Segmental glomerular damage and mesangial cell proliferation are more frequent in the idiopathic form (25). Some studies have documented the simultaneous presence of subendothelial and mesangial deposits in HBV-MN (26, 27).

Immune complexes may also be formed by implant antigens, and the presence of complement factors, platelet aggregation, and polymorphonuclear leukocytes may justify glomerular damage (28).

Finally, the direct effect of the virus has been suggested in HBV-MN also. Several studies have found HBV DNA in the nucleus and cytoplasm of epithelial and mesangial cells (29).

In the vast majority of patients, pathological basis is not possible to distinguish the HBV-related MN from the idiopathic MN. The only method available is based on the finding of circulating anti-phospholipase A2 receptor Ab (30, 31).

Membranoproliferative glomerulonephritis

MPGN is the second most common glomerulonephritis in HBV-positive patients. It is characterized by lobular aspects of the glomeruli because of mesangial proliferation. The splitting of glomerular basement membrane (GBM) is due to the infiltration of mesangial cells and their deposition in the subendothelial space of immune complexes containing HBsAg because of its size (32–34). Type 1 and type 3 MPGN have been observed in HBV-positive patients, while type 2 has been never observed (35).

Presence of mixed cryoglobulinemia (polyclonal IgM and IgG) has been described in HBV-positive patients. As cryoglobulinemia is mostly typical of HCV infection, a co-infection of HBV-HCV should be excluded.

HBV-positive patients with cryoglobulinemia have nephrotic syndrome, frequently with acute kidney injury (AKI) and vasculitis with low C3 and C5 levels in serum.

Polyarteritis nodosa

Although PAN is not strictly a renal disease, its evidence is high in HBV-positive patients with occurrence of a renal disease. PAN is a vasculitis with necrosis of medium size vessels due to deposition of HBsAg antibodies immune complexes (36).

With respect to idiopathic PAN, HBV patients have a more severe disease with frequent evolution to AKI due to renal ischemia and infarction. Arthralgia, fever, and cutaneous lesions are present. Additionally, elevated hypertension and renal infarctions of the cortex are also present. A case of HBV-positive patient with associated PAN and membranous nephropathy has been described by Mouthon et al. (37).

Other glomerulonephritis

The first description of mesangial proliferative glomerulonephritis with mesangial deposition of IgA and HBsAg or HBcAg has been made by Nagy et al. (38). Lai et al. (39) described a larger series of patients with HBV-associated mesangial proliferative glomerulonephritis. Approximately 20% of patients developed progressive renal failure within 4 years of follow-up, but this finding was not confirmed by others (40).

Relationship between FSGS and HBV is debated. Two cases have been described by Khaira et al. (41). The finding of HBsAg or HbcAg in the glomeruli in the absence of immunoglobulins suggests the role of a direct pathogenic effect of the virus.

MCD and diffused proliferative glomerulonephritis have been described in HBV-positive patients (42), but because of few cases reported, more confirmative studies are needed.

Diagnosis

The diagnosis of an HBV-related renal disease should be suspected for any HBV-positive patient with an abnormal urine analysis or a reduced renal function.

Patients with proteinuria, higher than 1 g (24 h), and microematuria are suspected for glomerular lesions. In such cases, a renal biopsy is necessary to confirm the suspected diagnosis (Figure 2). The diagnosis of HBV-related glomerular disease is confirmed by finding monoclonal antibodies and one or more HBV antigens (HBsAg, HBCAg, or HBeAg), although in one study only 39% of biopsies were positive (43). In the case of HBV-related PAN, urine-analysis may be negative, and a definitive diagnosis should be made by angiography (44).

Treatment

The vast majority of our knowledge on the treatment of HBV-related GNs relies on studies on membranous nephropathy, while data on MPGN or other glomerular diseases principally refer to case reports.

The main goal of the treatment is to reduce viral load. Antiviral treatment is effective in inducing HBV clearance.
and proteinuria remission (45, 46). In 2012, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines on glomerulonephritis recommended interferon alpha (IFNα) with nucleos(t)ide analogs (NAs) as the treatment of choice for HBV-GN (47).

Initially, the antiviral treatment was based on IFNα and lamivudine (LMV). Their use was effective in reducing proteinuria, principally in children with membranous nephropathy (48, 49). According these studies the renal prognosis was different in children and adults. Indeed, the occurrence of ESRD was 3% in children and 30% in adults.

Main drawback of LMV was the appearance of mutants resistant to therapy (50).

The peginterferon (PEG-IFN) alpha-2a is a more powerful treatment because it has both immune regulatory and antiviral action (51).

IFNα could induce proliferation of T lymphocytes and helper T cells (52).

Patients affected with HBV-related MN have a reduced TCD28-related cytotoxic activity, and IFNα treatment has an effective activity in 30–40% of patients with clearance of HBeAg (53).

Other NAs, in addition to LMV, used to date are entecavir (ETV), adefovir (ADV), telbivudine (TBV), and tenofovir (TAF), although LMV, ADV, and TBV are not recommended for treating chronic HBV infection (54).

ETV is effective with low resistance (55). Its dosage should be reduced according to renal function (56). ADV is effective for liver improvement, viral suppression, and biochemical improvement in patients resistant to LMV (57, 58). A major drawback of ADV is dose-dependent nephrotoxicity that could be avoided by maintaining a dose of 10 mg/daily (59, 60).

Use of TBV is limited due to the emergence of drug resistance that may reach 25.1% in 2 years of treatment (61, 62). Additionally, TBV may cause myopathy and peripheral neuropathy (63).

TAF is a better-known NA and is used as two variants: tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).

TDF is effective on HBV, but is nephrotoxic because of tubular injury (63). Because of this fact, TDF should be avoided in the treatment of HBV-related GN. More promising is TAF, which seems to have a reduced nephrotoxicity with a similar antiviral action (64, 65). TAF seems to have a higher antiviral activity and reduced nephrotoxicity than TDF, though few studies have compared the two drugs.

The WHO (56) recommends the dose reduction of TAF and ETV according to renal function (creatinine clearance) as shown in Table 1.

Although the aim of this study was to review principal treatments for HBV-related GN, briefly we report the conclusions of the Swedish guidelines (66) for the use of PEG-IFN and NAs.

PEG-IFN has a weak antiviral effect compared to NAs. A small number of HBeAg-positive and negative patients obtained HBsAg clearance. In addition, PEG-IFN is poorly tolerated and necessitates parenteral administration.

NAs have a major potency in elimination of virus. ETV, TDF, and TAF are recommended because these drugs have a higher barrier to drug resistance. On the contrary, LMV, ADV, and TBV with low barrier to drug resistance are not recommended.

ETV, whose dose should be reduced according eGFR, is the preferred treatment for naïve, non-cirrhotic HBeAg-positive patients. Attention should be paid to cross-resistance with LMV.

TDF is a highly effective treatment and has been approved as a monotherapy for the treatment of HBV. Risks of renal side effects do exist; hence, renal function should be monitored frequently.

TAF has the same mode of action as that of TDF, with fewer side effects on the kidney, and does not need to be
Table 1: Recommended dose reduction or dosing interval for tenofovir and entecavir.

|                | CrCl (mL/min) |                                                                 |
|----------------|--------------|------------------------------------------------------------------|
|                |              | 50                                                               |
|                |              | 30–49                                                           |
|                |              | 10–29                                                           |
| Tenofovir (TAF)| 300 mg every 24 h | 300 mg every 48 h | 300 mg every 72 h | Every 7 days |
| Entecavir (ETV)| 1 mg once daily | 0.5 mg once daily | 0.3 mg once daily | 0.1 mg once daily |

CrCl: creatinine clearance.

Table 2: Outcomes from treatment of HBeAg-positive and negative patients, 6-month and after 1-year treatment with PEG-IFN, and after 1-year treatment with nucleos(t)ide analogs (NAs).

|                | PEG-IFN alpha 2a | LMV | TBV | ETV | ADV | TDF | TAF |
|----------------|------------------|-----|-----|-----|-----|-----|-----|
| Dose           | 180 μg           | 100 mg | 600 mg | 0.5 mg | 10 mg | 245 mg | 25 mg |
| HBeAg-positive |                  |     |     |     |     |     |     |
| Anti-HBe seroconversion | 32% | 16–18% | 22% | 21% | 12–18% | 21% | 10% |
| HBV DNA < 60–80 IU/mL | 14% | 36–44% | 60% | 67% | 13–21% | 76% | 64% |
| ALT > ULN      | 41%              | 41–72% | 77% | 68% | 48–54% | 68% | 72% |
| Loss of HBsAg  | 3%               | 0–1%  | 0.5% | 2%  | 0%  | 3%  | 1%  |
| HBeAg-negative |                  |     |     |     |     |     |     |
| HBV DNA < 60–80 IU/mL | 19% | 72–73% | 88% | 90% | 51–63% | 93% | 94% |
| ALT < normal upper limit | 59% | 71–79% | 74% | 78% | 72–77% | 76% | 83% |
| Loss of HBsAg  | 4%               | 0%   | 0%  | 0%  | 0%  | 0%  | 0%  |

PEG-IFN: peginterferon; LMV: lamivudine; TBV: telbivudine; ETV: entecavir; ADV: adefovir; TDF: tenofovir; TAF: tenofovir.

LAM, TBV, and ETV are nucleoside analogues; and ADV, TDF, and TAF are nucleotide analogues.

monitored, although not recommended for patients with a very low eGFR.

The Swedish guidelines (66) report the outcomes of different NAs in HBeAg-positive and HBeAg-negative patients (Table 2).

Summarizing, the wider experience of the effects of antiviral treatments in HBV-GN is based on the studies conducted with LMV and IFNα therapy. Studies comparing the efficacy of new NAs and IFNα are still lacking. Anyway, HBV-GN goes into remission with the elimination of viral antigen (67–69). This fact favors the use of NAs with high potency. However, more studies are needed to confirm this point.

Immunosuppressants are also used frequently in the treatment of HBV-GN.

The usefulness of steroids is debated because the inhibition of the immune system may favor HBV replication (70). In a meta-analysis study, the steroid efficacy is not proved (45). In this study, both proteinuria remission and HBeAg clearance were obtained with the use of antiviral agents.

Administration of steroids is not recommended principally in patients with high viral load.

Similarly, the use of rituximab and cytotoxic agents may cause fatal complications (71, 72).

Only in the treatment of HBV-PAN, the association of steroids and plasmapheresis has been used successfully (73).

Conflict of interest

The authors declare no potential conflict of interest with respect to the research, authorship, and/or publication of this article.
References

1. Centers for Disease Control and Prevention (CDC). Hepatitis B vaccination coverage among adults – United States, 2004. MMWR Morb Mortal Wkly Rep. 2006;55:509–11.

2. Lin CL, Kao JH. Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):249–55. http://dx.doi.org/10.1016/j.bpg.2017.04.010

3. Gilbert RD, Wiggelinkhuizen J. The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol. 1994 Feb;8(1):11–14. http://dx.doi.org/10.1007/BF00868249

4. Kusakabe A, Tanaka Y, Kurbanov F, Goto K, Tajiri H, Murakami J, et al. Virological features of hepatitis B virus-associated nephropathy in Japan. J Med Virol. 2007 Sep;79(9):1305–11. http://dx.doi.org/10.1002/jmv.20941

5. Howard CR. The biology of hepadnaviruses. J Gen Virol. 1986 Jul;67(Pt 7):1215–35. http://dx.doi.org/10.1099/0022-1087-67-7-1215

6. Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res. 2007 Aug;127(2):164–70. http://dx.doi.org/10.1016/j.virusres.2007.02.021

7. Jaryal A, Kumar V, Sharma V. Renal disease in patients infected with hepatitis B virus. Trop Gastroenterol. 2015 Oct–Dec;36(4):220–8. http://dx.doi.org/10.1016/j.tjem.2015.09.007

8. Pyropoulos NT, Reddy KR. Extra hepatic manifestations of chronic viral hepatitis. Curr Gastroenterol Rep. 2005 Sep;7(3):243–51. http://dx.doi.org/10.1007/s11894-004-0044-1

9. Gupta A, Quigg RJ. Glomerular diseases associated with hepatitis B and C. Adv Chronic Kidney Dis. 2015 Sep;22(5):343–51. http://dx.doi.org/10.1053/j.ackd.2015.06.003

10. Chen L, Wu C, Fan X, Gao J, Yin H, Wang T, et al. Replication and infectivity of hepatitis B virus in HBV-related glomerulonephritis. Int J Infect Dis. 2009 May;13(3):394–8. http://dx.doi.org/10.1016/j.ijid.2008.08.014

11. Ozawa T, Levisohn P, Orsini E, McIntosh RM. Acute immune complex disease associated with hepatitis B. Etiopathogenic and immunopathologic studies of the renal lesion. Arch Pathol Lab Med. 1976 Sep;100(9):484–6.

12. Takekoshi Y, Tochimaru H, Nagata Y, Itami N. Immunopathogenetic mechanisms of hepatitis B virus-related glomerulopathy. Kidney Int Suppl. 1991 Dec;35:S34–S9.

13. Johnson RJ, Cousser WG. Hepatitis B infection and renal disease: Clinical, immunopathogenetic and therapeutic considerations. Kidney Int. 1990 Feb;37(2):663–76. http://dx.doi.org/10.1038/ki.1990.32

14. Gregorek H, Jung H, Uhranowicz G, Madalinski K. Immune complexes in sera of children with HBV-mediated glomerulonephritis. Arch Immunol Ther Exp (Warsz). 1986;34(1):73–83.

15. Namguk M, Cousser WG. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol. 2005 Sep;9(3):183–91. http://dx.doi.org/10.1007/s10157-005-0357-8

16. Ren J, Wang L, Chen Z, Ma ZM, Zhu HG, Yang DL, et al. Gene expression profile of transgenic mouse kidney reveals pathogenesis of hepatitis B virus-associated nephropathy. J Med Virol. 2006 May;78(5):551–60. http://dx.doi.org/10.1002/jmv.20575

17. He XY, Fang LJ, Zhang YF, Sheng FY, Zhang XR, Guo MY. In situ hybridization of hepatitis B DNA in hepatitis B-associated glomerulonephritis. Pediatr Nephrol. 1998 Feb;12(2):117–20. http://dx.doi.org/10.1007/s004670050417

18. Dao Z, Ding J, Yin C, Wang L, Liu W. Purified hepatitis B virus induces human mesangial cell proliferation and extracellular matrix expression in vitro. Virol J. 2013 Oct 4;10:300–4. http://dx.doi.org/10.1186/1743-422X-10-300

19. Bhimma R, Hammond MG, Covadima HM, Adhikari M, Connolly CA. HLA class I and II in black children with hepatitis B virus-associated membranous nephropathy. Kidney Int. 2002 Apr;61(4):1410–15. http://dx.doi.org/10.1046/j.1523-1755.2002.00328.x

20. Park MH, Song EY, Ahn C, Oh KH, Yang J, Kang SJ, et al. Two subtypes of hepatitis B virus-associated glomerulonephritis are associated with different HLA-DR2 alleles in Koreans. Tissue Antigens. 2003 Dec;62(6):505–11. http://dx.doi.org/10.1046/j.1399-0039.2003.00141.x

21. Hui D, Yan X, Wei J, Ruixia M, Guangju G. Significance of mutations in hepatitis B virus gene X for the pathogenesis of HB-associated glomerulonephritis. Acta Virol. 2014;58(3):278–81. http://dx.doi.org/10.4149/av_2014_03_278

22. Bhimma R, Covadima HM. Hepatitis B virus-associated nephropathy. Am J Nephrol. 2004 Mar–Apr;24(2):198–211. http://dx.doi.org/10.1159/0000707065

23. Liu XR, Shen Y, Yang YH. Membranous glomerulopathy associated with hepatitis B infection. J Pediatr (new series). 2008;13(1):23–9.

24. Lai KN, Li PK, Lui SF, Au TC, Tam JS, Tong KL, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med. 1991 May 23;324(21):1457–63. http://dx.doi.org/10.1056/NEJM199105233242103

25. Li P, Wei RB, Tang L, Wu J, Zhang XG, Chen XM. Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy. Clin Nephrol. 2012 Dec;78(6):456–46. http://dx.doi.org/10.5414/CN107615

26. Lee HS, Choi Y, Yu SH, Koh HL, Kim MJ, Ko KW. A renal biopsy study of hepatitis B virus-associated nephropathy in Korea. Kidney Int. 1988 Oct;34(4):537–543. http://dx.doi.org/10.1038/ki.1988.215

27. Collins AB, Bhan AK, Dienstag JL, Colvin RB, Haupert GT Jr, Mushahwar IK, et al. Hepatitis B immune complex glomerulonephritis: Simultaneous glomerular deposition of hepatitis B surface and e-antigens. Clin Immunol Immunopathol. 1983 Jan;26(1):137–53. http://dx.doi.org/10.1016/0091-1649(83)90182-4

28. Conjevararam HS, Hoofnagle JH, Austin HA, Park Y, Fried MW, Di Biseglie AM. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology. 1995 Aug;109(2):540–6. http://dx.doi.org/10.1016/0016-5085(95)90343-7

29. Lai KN, Ho RT, Tam JS, Lai FM. Detection of hepatitis B virus DNA and RNA in kidneys of HBV-related glomerulonephritis. Kidney Int. 1996 Dec;50(6):1965–77. http://dx.doi.org/10.1038/ki.1996.519

30. Xie Q, Yan Li Y, Xue J, Xiong Z, Wang L, Sun Z, et al. Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy. Am J Nephrol. 2015;41(4–5):345–53. http://dx.doi.org/10.1159/000431331

31. Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011 Jun;22(6):1137–43. http://dx.doi.org/10.1681/ASN.2010090967

32. Kupin WL. Viral-associated GN: Hepatitis B and other viral infections. Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1529–33. http://dx.doi.org/10.2215/CJN.09180816
33. Lu Y, Shen P, Li X. Re-evaluation of the classification system for membranoproliferative glomerulonephritis. Contrib Nephrol. 2013;181:175–84. http://dx.doi.org/10.1159/000348478
34. Li SJ, Xu ST, Chen HP, Zhang MC, Xu F, Cheng SQ, et al. Clinical and morphologic spectrum of renal involvement in patients with HBV-associated cryoglobulinemia. Nephrology (Carlton). 2017 Jun;22(6):449–55. http://dx.doi.org/10.1111/ nep.12795
35. Ozdamar SO, Gucer S, Tinaztepe K. Hepatitis-B virus associated nephropathies: A clinicopathological study in 14 children. Pediatr Nephrol. 2003 Jan;18(1):23–8. http://dx.doi.org/10.1007/s00467-002-0978-z
36. Sharma A, Sharma K. Hepatotropic viral infection associated systemic vasculitides-hepatitis B virus associated polymyositis nodosa and hepatitis C virus-associated cryoglobulinemic vasculitis. J Clin Exp Hepatol. 2013 Sep;3(3):204–12. http://dx.doi.org/10.1016/j.jchep.2013.06.001
37. Mouthon L, Deblois P, Sauvaget F, Meyrier A, Callard P, Guillevin L. Hepatitis B virus-related polymyositis nodosa and membranous nephropathy. Am J Nephrol. 1995;15(3):266–9. http://dx.doi.org/10.1159/000168844
38. Nagy J, Bajtai G, Brash H, Sülé T, Ambrus M, Deák G, et al. The role of hepatitis B surface antigen in the pathogenesis of glomerulopathies. Clin Nephrol. 1979 Sep;12(3):109–16.
39. Lai KN, Lai FM, Tam JS, Vallance-Owen J. Strong association between IgA nephropathy and hepatitis B surface antigenemia in endemic areas. Clin Nephrol. 1988 May;29(5):229–34.
40. Sun IO, Hong YA, Park HS, Choi SR, Chung BH, Park CW, et al. Clinical characteristics and treatment of patients with IgA nephropathy and hepatitis B surface antigen. Ren Fail. 2013;35(4):446–51. http://dx.doi.org/10.3109/0886022X.2013.775659
41. Khaira A, Upadhyay BK, Sharma A, Das P, Mahajan S, Makhariya G, et al. Hepatitis B virus associated focal and segmental glomerulosclerosis: Report of two cases and review of literature. Clin Exp Nephrol. 2009 Aug;13(4):373–7. http://dx.doi.org/10.1007/s10157-008-0124-8
42. Zhou TB, Jiang ZP. Is there an association of hepatitis B virus infection with minimal change disease of nephrotic syndrome? A clinical observational report. Ren Fail. 2015 Apr;37(3):459–61. http://dx.doi.org/10.3109/0886022X.2014.1001711
43. Lai FM, Lai KN, Tam JS, Lui SF, To KF, Li PK. Primary glomerulonephritis with detectable glomerular hepatitis B virus antigens. Am J Surg Pathol. 1994 Feb;18(2):175–86. http://dx.doi.org/10.1097/00000478-199402000-00007
44. Lightfoot RW Jr, Michel BA, Bloch DA, Hunder GG, Kocbsky MD, Dimsdale JH, et al. The role of hepatitis B surface antigen in the pathogenesis of systemic vasculitides-hepatitis B virus associated polyarteritis nodosa. Arthritis Rheum. 1990 Aug;33(8):1088–93. http://dx.doi.org/10.1002/art.1780330805
45. Zhang Y, Zhou JH, Yin XL, Wang FY. Treatment of hepatitis B virus-associated glomerulonephritis: A meta-analysis. World J Gastroenterol. 2010 Feb 14;16(6):770–7. http://dx.doi.org/10.3748/wjg.v16.i6.770
46. Fabrizi F, Lunghi G, Dixit V, Martin P. Meta-analysis: Antiviral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther. 2006 Nov 15;24(10):1413–22. http://dx.doi.org/10.1111/j.1365-2036.2006. 03151.x
47. Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: Reading between the (guide) lines – Application to the individual patient. Kidney Int. 2012 Oct;82(8):840–856. http://dx.doi.org/10.1038/ki.2012.280
48. Okuse C, Yotsuyanagi H, Yamada N, Ikeda H, Takahashi H, Suzuki M, et al. Successful treatment of hepatitis B virus-associated membranous nephropathy with lamivudine. Clin Nephrol. 2006 Jan;65(1):53–6. http://dx.doi.org/10.5414/CNP55053
49. Tang S, Lai FM, Lui YH, Tang CS, Kung NN, Ho YW, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int. 2005 Oct;68(4):1750–8. http://dx.doi.org/10.1111/j.1523-1755.2005.00591.x
50. Lapinski TW, Flisiak R, Jaroszewicz J, Michalewicz M, Kowalezkut O. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J Gastroenterol. 2005 Jan 21;11(3):400–2. http://dx.doi.org/10.3748/wjg.v11.i3.400
51. Cooksey WG, Piratsivuth T, Lee SD, Mahaehai V, Chao YC, Tanwandeet T, et al. Peginterferon alpha-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003 Jul;10(4):298–305. http://dx.doi.org/10.1046/j.1365-2893.2003.00450.x
52. Haria M, Benfield P. Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs. 1995 Nov;50(5):873–96. http://dx.doi.org/10.2165/00003495-199550050-00007
53. Di Bisceglie AM. Long-term outcome of interferon-alpha therapy for chronic hepatitis B. J Hepatol. 1995;22(1 Suppl):65–7.
54. European Association for the Study of the Liver. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370–98.
55. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009 May;49(5):1503–14. http://dx.doi.org/10.1002/hep.22841
56. World Health Organization (WHO). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva, Switzerland: WHO; 2015 March; pp. 74–6.
57. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003 Feb 27;348(9):808–16. http://dx.doi.org/10.1056/NEJMoa020681
58. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003 Feb 27;348(9):800–7. http://dx.doi.org/10.1056/NEJMoa021812
59. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003 Feb 27;348(9):800–7. http://dx.doi.org/10.1056/NEJMoa021812
60. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HB eAg-negative chronic hepatitis B. N Engl J Med. 2005 Jun 30;352(26):2673–81. http://dx.doi.org/10.1056/NEJMoa042957
61. Izzedine H, Hulot JS, Launay-Vacher V, Marcellini P, Hadziyannis SJ, Currie G, et al. Renal safety of adefovir dipivoxil for HB eAg-negative chronic hepatitis B. N Engl J Med. 2003 Feb 27;348(9):808–16. http://dx.doi.org/10.1056/NEJMoa020681
62. World Health Organization (WHO). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva, Switzerland: WHO; 2015 March; pp. 74–6.
62. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007 Dec 20;357(25):2576–88. http://dx.doi.org/10.1056/NEJMoa066422

63. Fung J, Seto WK, Lai CL, Yuen MF. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol. 2014 Mar;29(3):428–34. http://dx.doi.org/10.1111/jgh.12499

64. Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018 Apr;68(4):672–81. http://dx.doi.org/10.1016/j.jhep.2017.11.039

65. Viganò M, Loglio A, Grossi G, Lampertico P. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? Expert Rev Anti Infect Ther. 2018 Feb;16(2):153–61. http://dx.doi.org/10.1080/14787210.2018.1428561

66. Westin J, Aleman S, Castedal M, Duberg AS, Eilard A, Fischler B, et al. Management of hepatitis B virus infection, updated Swedish guidelines. Infect Dis (Lond). 2020 Jan;52(1):1–22. http://dx.doi.org/10.1080/23744235.2019.1675903

67. Igarashi T, Shimizu A, Igarashi T, Hanaoka K, Yoshizaki K, Shigemori T, et al. Seroconversion of hepatitis B envelope antigen by entecavir in a child with hepatitis B virus-related membranous nephropathy. J Nippon Med Sch. 2013;80(5):387–95. http://dx.doi.org/10.1272/jnms.80.387

68. Mahajan V, D’Cruz S, Nada R, Sachdev A. Successful use of entecavir in hepatitis B-associated membranous nephropathy. J Trop Pediatr. 2018 Jun 1;64(3):249–52. http://dx.doi.org/10.1093/troped/pxy058

69. Yang YF, Xiong QF, Zhao W, Zhong YD. Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy. Clin Res Hepatol Gastroenterol. 2012 Oct;36(5):e89–92. http://dx.doi.org/10.1016/j.clinre.2012.03.033

70. Lai KN, Tam JS, Lin HJ, Lai FM. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenemia. Nephron. 1990;54(1):12–7. http://dx.doi.org/10.1159/000185802

71. Hamada T, Kumashiro R, Koga Y, Hino T, Furudera S, Sakisaka S, et al. Fatal acute hepatitis B virus infection while receiving immunosuppressants after renal transplantation. Intern Med. 1993 Jul;32(7):547–51. http://dx.doi.org/10.2169/internalmedicine.32.547

72. Lai MK, Huang CC, Chu SH, Chuang CK, Fong MT. Renal transplantation in hepatitis B carriers: Comparison of aza-thioprine- and cyclosporine-treated recipients. Clin Transpl. 1989:281–6. PMID: 2487573

73. Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, et al. Hepatitis B virus-associated polyarteritis nodosa: Clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore). 2005 Sep;84(5):313–22. http://dx.doi.org/10.1097/01.md.0000180792.80212.5e